1. Cell Cycle/DNA Damage
  2. PARP


PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death. The PARP family comprises 17 members. They have all very different structures and functions in the cell. PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2) have a confirmed PARP activity. Others include PARP3, PARP6, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. PARP is found in the cell’s nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair.

PARP Related Products (32):

Cat. No. Product Name Effect Purity
  • HY-10162
    Olaparib Inhibitor 99.71%
    Olaparib is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP-1 and PARP-2, respectively.
  • HY-16106
    BMN-673 Inhibitor 99.83%
    BMN-673 is a novel PARP1/2 inhibitor with IC50 of 0.57 nM for PARP1.
  • HY-10619
    MK-4827 Inhibitor 99.17%
    MK-4827 is an excellent PARP1 and PARP2 inhibitor with IC50 of 3.8 and 2.1 nM, respectively.
  • HY-15147
    XAV-939 Inhibitor 98.04%
    XAV-939 is a selective Wnt pathway β-catenin-mediated transcription inhibitor and axin stabilizing agent with IC50 values of 11 and 4 nM for the inhibition of TNKS1 and TNKS2, respectively.
  • HY-10617
    Rucaparib phosphate Inhibitor 99.89%
    Rucaparib (phosphate) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP domains.
  • HY-104044
    Pamiparib Inhibitor 99.91%
    Pamiparib is a PARP inhibitor which can be used for the treatment of various cancers including the solid tumor, extracted from patent WO 2013097225 A1.
  • HY-U00422
    K-756 Inhibitor
    K-756 is a direct and selective tankyrase (TNKS) inhibitor, which inhibits the ADP-ribosylation activity of TNKS1 and TNKS2 with IC50s of 31 and 36 nM, respectively.
  • HY-10129
    Veliparib Inhibitor >98.0%
    Veliparib is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively.
  • HY-13688
    PJ34 hydrochloride Inhibitor
    PJ34 hydrochloride is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.
  • HY-B0150
    Nicotinamide Inhibitor >98.0%
    Nicotinamide is a water-soluble vitamin, an active component of coenzymes NAD and NADP, and acts as poly (ADP-ribose) polymerase (PARP) inhibitor.
  • HY-10619B
    MK-4827 tosylate Inhibitor 99.52%
    MK-4827 tosylate is an excellent PARP1 and PARP2 inhibitor with IC50 of 3.8 and 2.1 nM, respectively.
  • HY-10130
    Veliparib dihydrochloride Inhibitor 99.62%
    Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively.
  • HY-12418
    E7449 Inhibitor 99.09%
    E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2; enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.
  • HY-13536
    AZD-2461 Inhibitor 98.12%
    AZD2461 is a novel PARP inhibitor, which has the potential to avoid the olaparib resistence mediated by Pgp.
  • HY-13990
    NVP-TNKS656 Inhibitor 99.14%
    NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.
  • HY-12015
    BSI-201 Inhibitor 99.65%
    BSI-201 (Iniparib; NSC-746045) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC).
  • HY-12438
    G007-LK Inhibitor 99.24%
    G007-LK displays high selectivity toward tankyrases 1 and 2 with biochemical IC50 values of 46 nM and 25 nM, respectively, and a cellular IC50 value of 50 nM combined with an excellent pharmacokinetic profile in mice.
  • HY-16106A
    BMN-673 8R,9S
    BMN-673 8R,9S is an enantiomer of BMN-673. BMN-673 is a novel PARP1/2 inhibitor with IC50 of 0.57 nM for PARP1.
  • HY-10614
    A-966492 Inhibitor 98.59%
    A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.
  • HY-13968
    JW 55 Inhibitor 99.16%
    JW 55 is a potent and selective β-catenin signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC50s of 1.9 μM and 830 nM respectively.